|
1
|
Vislovukh A, Vargas TR, Polesskaya A and
Groisman I: Role of 3′-untranslated region translational control in
cancer development, diagnostics and treatment. World J Biol Chem.
5:40–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Rooij E and Kauppinen S: Development
of microRNA therapeutics is coming of age. EMBO Mol Med. 6:851–864.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu J, Zheng Z, Wang J, Sun J, Wang P,
Cheng X, Fu L, Zhang L, Wang Z and Li Z: Different miRNA expression
profiles between human breast cancer tumors and serum. Front Genet.
5:1492014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Corcoran C, Friel AM, Duffy MJ, Crown J
and O'Driscoll L: Intracellular and extracellular microRNAs in
breast cancer. Clin Chem. 57:18–32. 2011. View Article : Google Scholar
|
|
6
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar
|
|
7
|
Greene SB, Herschkowitz JI and Rosen JM:
Small players with big roles: microRNAs as targets to inhibit
breast cancer progression. Curr Drug Targets. 11:1059–1073. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Le Quesne J and Caldas C: Micro-RNAs and
breast cancer. Mol Oncol. 4:230–241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsai CH, Tsai HC, Huang HN, Hung CH, Hsu
CJ, Fong YC, Hsu HC, Huang YL and Tang CH: Resistin promotes tumor
metastasis by down-regulation of miR-519d through the AMPK/p38
signaling pathway in human chondrosarcoma cells. Oncotarget.
6:258–270. 2015.
|
|
10
|
Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ
and Tang CH: CTGF increases matrix metalloproteinases expression
and subsequently promotes tumor metastasis in human osteosarcoma
through down-regulating miR-519d. Oncotarget. 5:3800–3812.
2014.PubMed/NCBI
|
|
11
|
Pang Y, Mao H, Shen L, Zhao Z, Liu R and
Liu P: MiR-519d represses ovarian cancer cell proliferation and
enhances cisplatin-mediated cytotoxicity in vitro by targeting
XIAP. Onco Targets Ther. 7:587–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S,
Callegari E, et al: In hepatocellular carcinoma miR-519d is
up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21,
PTEN, AKT3 and TIMP2. J Pathol. 227:275–285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hou YY, Cao WW, Li L, Li SP, Liu T, Wan
HY, Liu M, Li X and Tang H: MicroRNA-519d targets MKi67 and
suppresses cell growth in the hepatocellular carcinoma cell line
QGY-7703. Cancer Lett. 307:182–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haura EB, Turkson J and Jove R: Mechanisms
of disease: Insights into the emerging role of signal transducers
and activators of transcription in cancer. Nat Clin Pract Oncol.
2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walker SR, Xiang M and Frank DA: Distinct
roles of STAT3 and STAT5 in the pathogenesis and targeted therapy
of breast cancer. Mol Cell Endocrinol. 382:616–621. 2014.
View Article : Google Scholar
|
|
16
|
Clevenger CV: Roles and regulation of stat
family transcription factors in human breast cancer. Am J Pathol.
165:1449–1460. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Haghikia A, Hoch M, Stapel B and
Hilfiker-Kleiner D: STAT3 regulation of and by microRNAs in
development and disease. JAK-STAT. 1:143–150. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao G, Zhang JG, Shi Y, Qin Q, Liu Y,
Wang B, Tian K, Deng SC, Li X, Zhu S, et al: Correction: miR-130b
is a prognostic marker and inhibits cell proliferation and invasion
in pancreatic cancer through targeting STAT3. PLoS One.
8:e738032013. View Article : Google Scholar
|
|
19
|
Zhang X, Tang J, Zhi X, Xie K, Wang W, Li
Z, Zhu Y, Yang L, Xu H and Xu Z: miR-874 functions as a tumor
suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway
in gastric cancer. Oncotarget. 6:1605–1617. 2015.PubMed/NCBI
|
|
20
|
Xiao Y, Wang J, Yan W, Zhou Y, Chen Y,
Zhou K, Wen J, Wang Y and Cai W: Dysregulated miR-124 and miR-200
expression contribute to cholangiocyte proliferation in the
cholestatic liver by targeting IL-6/STAT3 signalling. J Hepatol.
62:889–896. 2015. View Article : Google Scholar
|
|
21
|
Jiang J, Li Z, Yu C, Chen M, Tian S and
Sun C: MiR-1181 inhibits stem cell-like phenotypes and suppresses
SOX2 and STAT3 in human pancreatic cancer. Cancer Lett.
356:962–970. 2015. View Article : Google Scholar
|
|
22
|
Zhang H, Cai K, Wang J, Wang X, Cheng K,
Shi F, Jiang L, Zhang Y and Dou J: MiR-7, inhibited indirectly by
lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of
breast cancer stem cells by downregulating the STAT3 pathway. Stem
Cells. 32:2858–2868. 2014. View Article : Google Scholar : PubMed/NCBI
|
